REGENERON PHARMACEUTICALS, INC. — Director's Dealing 2017

Jun 23, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: REGENERON PHARMACEUTICALS INC (REGN)
CIK: 0000872589
Period of Report: 2017-06-21

Reporting Person: Aberman Michael S (SVP Strategy Investor Relation)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2017-06-21	Common Stock	M	4500	$30.63	Acquired	9193	Direct
2017-06-21	Common Stock	F	270	$510.02	Disposed	8923	Direct
2017-06-21	Common Stock	F	1961	$510.02	Disposed	6962	Direct
2017-06-22	Common Stock	S	395	$525.21	Disposed	6567	Direct
2017-06-22	Common Stock	S	100	$526.02	Disposed	6467	Direct
2017-06-22	Common Stock	S	100	$529.61	Disposed	6367	Direct
2017-06-22	Common Stock	S	100	$530.66	Disposed	6267	Direct
2017-06-22	Common Stock	S	274	$531.51	Disposed	5993	Direct
2017-06-22	Common Stock	S	200	$532.27	Disposed	5793	Direct
2017-06-22	Common Stock	S	200	$533.48	Disposed	5593	Direct
2017-06-22	Common Stock	S	200	$534.51	Disposed	5393	Direct
2017-06-22	Common Stock	S	400	$536.52	Disposed	4993	Direct
2017-06-22	Common Stock	S	100	$537.5	Disposed	4893	Direct
2017-06-22	Common Stock	S	100	$538.3	Disposed	4793	Direct
2017-06-22	Common Stock	S	100	$541.0	Disposed	4693	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2017-06-21	Non-Qualified Stock Option (right to buy)	$30.63	M	4500	Disposed	2020-12-14	Common Stock (4500)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	11805	Indirect
Common Stock	448	Indirect

Footnotes

F1: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).

F2: Represents volume-weighted average price of sales of 395 shares of Company stock on June 22, 2017 at prices ranging from $525.00 to $525.83. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 22, 2017 at each separate price.

F3: Represents volume-weighted average price of sales of 274 shares of Company stock on June 22, 2017 at prices ranging from $531.05 to $531.85. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 22, 2017 at each separate price.

F4: Represents volume-weighted average price of sales of 200 shares of Company stock on June 22, 2017 at prices ranging from $532.18 to $532.35. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 22, 2017 at each separate price.

F5: Represents volume-weighted average price of sales of 200 shares of Company stock on June 22, 2017 at prices ranging from $533.17 to $533.78. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 22, 2017 at each separate price.

F6: Represents volume-weighted average price of sales of 200 shares of Company stock on June 22, 2017 at prices ranging from $534.16 to $534.85. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 22, 2017 at each separate price.

F7: Represents volume-weighted average price of sales of 400 shares of Company stock on June 22, 2017 at prices ranging from $536.15 to $536.93. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 22, 2017 at each separate price.

F8: The stock option award vests in four equal annual installments, commencing one year after the date of grant.